1,976 Shares in AbbVie Inc. (NYSE:ABBV) Bought by Asset Planning Inc

Asset Planning Inc bought a new position in shares of AbbVie Inc. (NYSE:ABBV) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,976 shares of the company’s stock, valued at approximately $351,000.

A number of other hedge funds have also bought and sold shares of the company. White Pine Capital LLC raised its stake in AbbVie by 1.9% during the fourth quarter. White Pine Capital LLC now owns 5,773 shares of the company’s stock worth $1,026,000 after buying an additional 110 shares during the last quarter. V Square Quantitative Management LLC grew its holdings in AbbVie by 3.3% in the fourth quarter. V Square Quantitative Management LLC now owns 11,114 shares of the company’s stock worth $1,975,000 after purchasing an additional 350 shares during the period. Palacios Wealth Management LLC acquired a new stake in AbbVie in the fourth quarter worth $1,543,000. Compagnie Lombard Odier SCmA grew its holdings in AbbVie by 3.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 357,900 shares of the company’s stock worth $63,599,000 after purchasing an additional 11,491 shares during the period. Finally, Arcus Capital Partners LLC acquired a new stake in AbbVie in the fourth quarter worth $802,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

ABBV stock opened at $193.54 on Friday. AbbVie Inc. has a one year low of $153.58 and a one year high of $207.32. The stock has a market cap of $342.00 billion, a PE ratio of 80.64, a P/E/G ratio of 1.53 and a beta of 0.58. The firm has a 50 day simple moving average of $178.24 and a two-hundred day simple moving average of $185.91. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same quarter in the previous year, the firm posted $2.79 earnings per share. On average, analysts predict that AbbVie Inc. will post 12.32 EPS for the current fiscal year.

Insider Activity

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This represents a 20.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.25% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ABBV has been the subject of a number of research reports. Citigroup raised their price target on shares of AbbVie from $205.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. cut their price target on shares of AbbVie from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. Piper Sandler boosted their price target on shares of AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Morgan Stanley boosted their price target on shares of AbbVie from $224.00 to $239.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, Piper Sandler Companies restated an “overweight” rating and set a $220.00 price target on shares of AbbVie in a report on Tuesday, December 17th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $208.35.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.